Leon Chen is a Partner at The Column Group, a science-driven venture capital firm. See sector focus and contact routes.
Leon Chen is a Partner at The Column Group, a science-driven venture capital firm, having joined in 2019 after serving as a Venture Partner at Orbimed and a Partner at Skyline Ventures. He also founded KAI Pharmaceuticals, which was acquired by Amgen in 2012, and holds a PhD in Molecular Pharmacology from Stanford School of Medicine. Chen’s investment thesis focuses on early-stage and seed biotechnology companies in the United States, specifically those built on unique scientific platforms for drug discovery. The firm employs an “edge-to-edge” model to support companies from inception through exit, aiming to deliver multiple breakthrough therapeutics rather than short-term exits. Chen has acted as the lead partner on 13 deals, with his latest being Eikon Therapeutics, a drug discovery company. His notable portfolio includes board memberships at LogicBio Therapeutics, Tr1x, and Eikon Therapeutics, plus serving as Chairman at Velia. While no public writing or distinctive point of view is explicitly cited in the search results, his background as a biotech founder and long-time VC partner underscores a practical, science-first approach to company creatio
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like Leon Chen · Full investor directory · Investor access · Company funding database